Edge-to-Edge Repair in Atrial Secondary Tricuspid Regurgitation

Tricuspid regurgitation (TR) has been associated with higher morbimortality and a negative impact on quality of life. 

La insuficiencia renal post tratamiento borde a borde tricuspídeo impacta en el pronóstico

In most cases, its main cause is a condition of the left heart. However, in lower proportion, it may also be due to significant right atrium dilation compared against the right ventricle (Atrial Secondary Tricuspid Regurgitation, A-SRT). The latter has not been studied enough and little is known about its prognosis. 

Tricuspid edge-to-edge repair (T-TEER) has been shown safe and effective, improving quality of life and reducing hospitalization for cardiac failure. However, its efficacy in the context of A-SRT has not been thoroughly assessed.

This was a EuroTR Registry analysis including 641 patients with moderate to severe TR receiving T-TEER. 196 (30,5 %) of these patients presented A-SRT, while the rest had non-atrial secondary TR (N-SRT).

Read also: PULSE Registry Subanalysis: Radial vs. Femoral Secondary Access.

MitraClip, TriClip and PASCAL were used.

Mean patient age was 79. A-SRT patients showed higher prevalence of atrial fibrillation, less comorbidities and better biventricular function. Most were in functional class III-IV.

TR severity was 3+ in 47% of cases, 4+ in 41%, and 5+ in 18%.

After procedure, even though both groups saw TR reduction, the proportion of TR ≤ 2 was lower among A-SRT patients (86,9 % vs. 80,4 %; p=0,005).

Read also: Percutaneous Treatment of Tricuspid Regurgitation with K-CLIP.

At two-year follow-up, survival was significantly higher among A-SRT patients (66,7 % vs. 44,3 %; p<0,001), as was CF hospitalization reduction (66,3 % vs. 47,5 %; p<0,001). Both groups experienced improved functional class, but the proportion of patients with CF in functional class ≥ III was lower among A-SRT patients (38 % vs. 46 %; p=0,033). 

Conclusion

A-SRT is a common STR phenotype associated to effective reduction of TR and improved symptoms after T TEER. 

Original Title: Atrial Secondary Tricuspid Regurgitation Insights Into the EuroTR Registry.

Reference: Lukas Stolz, et al. JACC Cardiovasc Interv. 2024;17:2781–2791.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Dr. Carlos Fava
Dr. Carlos Fava
Member of the Editorial Board of solaci.org

More articles by this author

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

ACC 2025 | BHF PROTECT-TAVI: Are Cerebral Protection Systems Necessary in TAVI?

TAVI has seen a steady increase in use, though stroke continues to be one of its unwanted complications, mostly ischemic and, less frequently, hemorrhagic. The...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Radial Patency in Coronary Procedures: Is Heparin Enough or Should We Aim for Distal Transradial Access?

Transradial access is the preferred route in most coronary procedures due to its proven reduction in mortality compared to transfemoral access. However, one of...

SMART-CHOICE 3 | Efficacy and Safety of Clopidogrel vs Aspirin Monotherapy in High Risk Patients after Percutaneous Coronary Intervention

Courtesy of Dr. Juan Manuel Pérez. After post percutaneous coronary intervention (PCI) standard duration dual antiplatelet therapy (DAPT), the optimal long term monotherapy strategy is...

RACE Trial: Effect of Balloon Pulmonary Angioplasty and Riociguat on Right Ventricular Afterload and Function in Chronic Thromboembolic Pulmonary Hypertension

Even though pulmonary endarterectomy is the treatment of choice for chronic thromboembolic pulmonary hypertension (CTEPH), up to 40% of patients are not candidates because...